Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

AM-1710

Synthetic cannabilactone, CB2 agonist (Ki 17 nM, 17- to 54-fold selective over CB1).

FranceStatus changingInternationalNarcotic: generic clause
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₃H₂₈O₄

CID 11268660

Family
Synthetic CB receptor agonistResearch ligand or medicine
Molar mass
368.50 g/mol

Updated on

In plain terms

AM-1710 is a laboratory molecule, described in 2007 by chemists in Boston to study a receptor of the body called CB2. It enters the mouse brain poorly and, in rats, did not cause the usual effects of THC (lower temperature, slowed movement). It is not found in any hemp-based product; no study in humans was found.

Receptors and activity

Target network

CB2AgonistKi = 17 nM · mousecompetitive [3H]CP55,940 binding, HEK293 cells transfected with mouse CB2 (17 ± 10 nM); 17-fold selectivity over rat CB1; inhibits forskolin-stimulated cAMP and activates ERK1/2 (Li 2019); 54-fold selectivity reported in 2007
  • Activates
  • Binds or modulates

The lower the cited value, the closer the target sits to AM-1710: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of AM-1710.

Brain, side view
Body, front view
Blood

CB2CB2 found in 5 regions of the body

  1. SpleendenseHighly abundant in the spleen1
  2. Immune cellspresentMainly B cells and natural killer cells1
  3. SkinpresentKeratinocytes, mast cells and nerve fibres2
  4. GutpresentImmune cells of the colonic mucosa3
  5. BonepresentPresent on osteoclasts4

Map sources

  1. Galiègue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem, 1995 (new tab)
  2. Ständer S et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 2005 (new tab)
  3. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
  4. Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)

Cited values

  1. CB2AgonistKi = 17 nM · mouse63 out of 100

    Rahn et al., Pharmacol Biochem Behav 2011 (new tab) · competitive [3H]CP55,940 binding, HEK293 cells transfected with mouse CB2 (17 ± 10 nM); 17-fold selectivity over rat CB1; inhibits forskolin-stimulated cAMP and activates ERK1/2 (Li 2019); 54-fold selectivity reported in 2007

  2. CB1Binding (function not established)Ki = 282 nM · rat42 out of 100

    Rahn et al., Pharmacol Biochem Behav 2011 (new tab) · competitive [3H]CP55,940 binding, rat brain (282 ± 91 nM); functionally: low-potency competitive antagonist/inverse agonist on cAMP and ERK (KB around 10 µM) and low-efficacy agonist for arrestin (Dhopeshwarkar 2017)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

AM-1710 is a synthetic cannabilactone, related to cannabinol, described in 2007 by the Makriyannis group as a CB2-selective ligand: a CB2 agonist (Ki 17 nM at mouse CB2), 17-fold (Rahn et al. 2011) to 54-fold (Khanolkar et al. 2007) selective over CB1 depending on the assay. At CB1 it behaves as a low-potency competitive antagonist and inverse agonist on cAMP and ERK, and as a low-efficacy agonist for arrestin, hence the label "Janus" cannabinoid (Dhopeshwarkar et al. 2017). It crosses the blood-brain barrier poorly in mice (brain-to-plasma ratio 0.23 mL/g); in rats it produced no hypoactivity, hypothermia, tail-flick antinociception or motor ataxia from 0.1 to 10 mg/kg intraperitoneally, and produced antinociception to thermal but not mechanical stimulation (Rahn et al. 2011). In mouse pain models it sustainedly inhibited paclitaxel-induced allodynia, delayed the development of morphine tolerance and attenuated morphine-induced physical dependence, but did not suppress established allodynia induced by complete Freund's adjuvant or partial sciatic nerve ligation (Li et al. 2019); the effect on zalcitabine-induced neuropathy was absent in mice lacking CB2 in primary sensory neurons (Carey et al. 2023). These are preclinical results; no study in humans was found.

Key sources.

History

Source
An entirely synthetic molecule; no natural occurrence was found in the sources consulted. It was designed in the cannabilactone series, related to cannabinol, to obtain CB2-selective ligands (Khanolkar et al. 2007). It is known only as a research compound; no study in humans was found.

Origin

Laboratory synthesis

No biological pathway: AM-1710 is a synthetic compound of the cannabilactone class (benzo[c]chromen-6-ones), structurally related to cannabinol; no plant or animal enzymatic pathway producing it was found in the sources consulted.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

classical

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

No dedicated article.

References

  1. Khanolkar AD et al. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem, 2007 (new tab)PMID 18038967
  2. Rahn EJ et al. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav, 2011 (new tab)PMID 21382397
  3. Dhopeshwarkar A et al. Two Janus cannabinoids that are both CB2 agonists and CB1 antagonists. J Pharmacol Exp Ther, 2017 (new tab)PMID 27927913
  4. Li AL et al. Cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal. Mol Pharmacol, 2019 (new tab)PMID 30504240
  5. Wilkerson JL et al. Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. Brain Res, 2022 (new tab)PMID 34774500
  6. Carey LM et al. Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy. Pharmacol Res, 2023 (new tab)PMID 36417942
  7. PubChem, AM-1710, CID 11268660 (identifiers and properties) (new tab)

Identifiers

Names

IUPAC name
1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one
Other names
AM1710 · AM 1710 · cannabilactone 4b · 3-(1,1-dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo[b,d]pyran-6-one

Identifiers

Formula
C₂₃H₂₈O₄
PubChem CID
11268660(new tab)
InChIKey
ZAIKPEWFCSQNQB-UHFFFAOYSA-N
SMILES
CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(=O)C3=C2C=C(C=C3)OC)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.